UBE2L6

Across TCGA pan-cancer cohorts, UBE2L6 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated UBE2L6 data layer compared with 29 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher UBE2L6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2L6 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, COAD, and LSCC are the cancer types where UBE2L6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.181	0.625	.001	29	view →
COAD	DFS	Quartile	II,III,IV	0.868	1.000	.018	24	view →
LSCC	DFS	Median	II,III,IV	0.520	0.886	.002	9	view →
GBM	DFS	Median	All	0.654	0.775	.012	8	view →
HNSC	OS	Median	III,IV	1.000	0.946	.037	7	view →
CCRCC	DFS	Median	III,IV	0.548	0.813	.024	6	view →
LUAD	DFS	Median	II,III,IV	0.934	0.772	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

UBE2L6–PDAC (OS)

Open the PDAC breakdown →